1Charlotte K, Tony C, Min Wu, et al. Reconstruction of functionally normal and malignant human breast tissues in mice [J]. PNAS, 2004,101 (14) :4966-4971.
2Yoshikawa M, Ito A, Ishikawa T, et al. Drug resistance mediated by ABC transporters[J]. Gan To Kagaku Ryoho, 2004,31 (1):1-6.
3Molitemi A, Me'nard S, Valagussa P, et al. HER20verexpression and Doxorubicinin Adjuvant Chemotherapy for Resectable Breast Cancer[J].J Clin Oncol, 2003,21 (3) : 458-462.
4Ayers M, Symmans WF, Stec J, et al. Gene Expression Profiles Predict Complete Pathologic Response to Neoadjuvant Paclitaxel and Fluorouracil, Doxorubicin, and Cyclophosphamide Chemotherapy in Breast Cancer [J ]. J Clin Oncol, 2004, 22 (12) :2284-2293.
5Xu JM, Song ST, Tang ZM, et al. Predictive chemotherapy of advanced breast cancer directed by MTT assay in vitro[J]. Breast Cancer Res Treat, 1999,53 ( 1 ) : 77-85.
同被引文献22
1Kurbaeher CM, Cree IA. Chemosensitivity testing using microplate adenosine triphosphate-based luminescence measurements [J]. Methods Mol Med, 2005, 110 : 101-120.
2Ugurel S, Schadendorf D, Pfohler C, et al. In vitro drug sensitivity predicts response and survival after individualized sensitivity - directed chemotherapy in metastatic melanoma:a muhicenter phase Ⅱ trial of the Dermatologic Cooperative Oncology Group [ J]. Clin Cancer Res, 2006, 12 ( 18 ) :5454-5463.
3Kurbacher CM, Crecu OM, Stier U, et al. ATP chemosensitivity testing in ovarian and breast cancer: early clinical trials[ J ]. Recent Results Cancer Res, 2003, 16( 1 ) :221-230.
4Cree IA, Kurbacher CM, Lamont A, et al. A prospective randomized controlled trial of tumor chemosensitivity assay directed chemotherapy versus physician' s choice in patients with recurrent p!ati- num resistant ovarian cancer[ J]. Anticancer Drugs, 2007, 18 (9) : 1093-1101.
5Lau GI, too WT, Chow LW. Neoadjuvant chemotherapy for breast cancer determined by chemosensitivity assay achieves better tumor response [ J ]. Biomed Pharmacother, 2007, 61 (9) :562-565.
6Syed S,Rogers PA,Ganju V,et al.Bc1-2 predictive markers for breast cancer neoadjuvant chemotherapy[J].ANZJ Surg,2007,77(9):213-217.
7Lee A,PARKWC,YM HW,et al.Expression of c2erbB,cyclin D1 and estrogen receptor and their clinical implications in the invasive ductal carcinoma of the breast[J].Jpn J Clin Oncol,2007,37(9):708-714.
8Tanner M,Isola J.Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer[J].Scandinavian Breast Group Trial,2006,24(16):2409-2418.
